Disclosed is a solid phase pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and siponimod (BAF312 / 1-{ 4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl} -azetidine-3-carboxylic acid) or a pharmacologically acceptable salt (particularly the hemifumarate salt), solvate or hydrate thereof, wherein siponimod is in a mixture of materials which is free of basic compounds, with the exclusion of basic forms of siponimod itself. Also disclosed is a solid phase pharmaceutical composition such as a tablet comprising one or more pharmaceutically acceptable excipients and siponimod , wherein siponimod has a crystallinity of 80% or more and wherein the siponimod is in a mixture of materials which is free of basic compounds, with the exclusion of basic forms of siponimod itself.
